Clinical Trials Logo

Clinical Trial Summary

The central aim of this study is to investigate the optimal timing of vaccination in pregnant women. Therefore, pregnant women will be vaccinated against pertussis at different timepoints and blood and breast milk samples will be taken at several timepoints. The main objectives are to assess the impact of timing on humoral and cellular immune responses in pregnant women, on antibody characteristics transferred across the placenta and on transplacental transport efficiency. The impact of maternal pertussis vaccination and timing of maternal pertussis vaccination on breastmilk antibody composition will also be investigated, as well as the impact of vaccination during pregnancy on the mucosal uptake of breastmilk IgA antibodies by the infant respiratory and gastrointestinal tract.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06466629
Study type Observational
Source Universiteit Antwerpen
Contact Kirsten Maertens
Phone +32496717845
Email kirsten.maertens@uantwerpen.be
Status Recruiting
Phase
Start date July 1, 2021
Completion date April 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04807712 - Pediatric Pertussis in Ambulatory Settings
Completed NCT05234229 - Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
Completed NCT05461131 - Pertussis Challenge Study in Adults Vaccinated With BPZE1 Phase 2
Recruiting NCT05847322 - Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks N/A